Construction of a novel signature based on immune-related lncRNA to identify high and low risk pancreatic adenocarcinoma patients

Table 2 The association between anti-cancer drugs and risk scores of PAAD patients

Drugs with elevated IC50 values in high-risk group	Drugs with reduced IC50 values in high-risk group
PD.173,074 NVP.BEZ235 MK.2206 Mitomycin.C Methotrexate Vorinostat Lenalidomide PD.0332991 (Palbociclib) CEP.701 (Lestaurtinib) AZD8055 ATRA Temsirolimus AP.24,534 (Ponatinib) ABT.888 (Veliparib) SB.216,763 TW.37 Axitinib Metformin GDC.0449 EHT.1864 CCT007093 Camptothecin AMG.706 (Motesanib) VX.702 SB590885 QS11 ZM.447,439 BIRB.0796 Salubrinal Nutlin.3a NU.7441 KU.55,933 Elesclomol Nilotinib	GNF.2 Lapatinib Dasatinib AZD.0530 (Saracatinib) RDEA119 PD.0325901 AICAR AKT.inhibitor.VIII AUY922 (Luminespib) CI.1040 Bryostatin.1 Bortezomib BIBW2992 (Afatinib) A.443,654 Thapsigargin VX.680 BMS.536,924 CMK BMS.509,744 PHA.665,752 Bicalutamide PF.562,271 A.770,041 Epothilone.B GW843682X WZ.1.84 X17.AAG Z.LLNle.CHO CGP.082996 FTI.277 NSC.87,877 JW.7.52.1 S.Trityl.L.cysteine BI.2536

ISSN: 1471-230X